This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ionis Pharmaceuticals, Inc.
Drug Names(s): ISIS-14803
Deal Structure: January 2000, Isis and Elan formed HepaSense, a joint venture with the aim of jointly developing Isis-14803 to treat patients with chronic HCV. As part of this second joint venture between Isis and Elan, Elan purchased 298,000 shares of Isis common for $7.5 million, 12,015 shares of Isis Series A preferred for $12 million (convertible up to 60.1% of HepaSense or Isis common at 125% of 60-day trading average after June 30, 2002). lan will purchase additional $7.5 million of Isis common as milestone payments and has committed to purchase Isis convertible debt in the amount of Isis' share of the joint ventures funding.
In November 2002, Elan terminated its agreement with Isis and returned rights of this compound to Isis.
Perrigo and Elan
In December 2013, Perrigo and Elan announced that Perrigo has completed the acquisition of Elan in a cash and stock transaction valued on the date of the announcement at approximately US$8.6 billion. In connection with the acquisition,...See full deal structure in Biomedtracker
Partners: Perrigo Company PLC
Additional information available to subscribers only: